http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
( Su Rin Shin ),( Sang Hoon Park ),( Myung Seok Lee ),( Jin Woo Lee ),( June Sung Lee ),( Young Seok Kim ),( Moon Seok Choi ),( Sook Hyang Jeong ),( Joo Hyun Shon ) 대한간학회 2012 춘·추계 학술대회 (KASL) Vol.2012 No.1
Background: Because of the limited geographic distribution of hepatitis C virus (HCV) genotype 6, there are insufficient data on its response to available treatment. This study was aimed to evaluate the efficacy and safety of peginterferon plus ribavirin for genotype 6 chronic hepatitis C (CHC) patients in Korea. Methods: Data of 17 patients with genotype 6 CHC who were treated with peginterferon and ribavirin at 7 hospitals affiliated with Medical College in South Korea were reviewed. Results: There were 17 patients with genotype 6 (age 35-54 years, 41% male). Among them, data of 10 patients were from K(G)yeonggi-Incheon Peginterferon Alpha and Ribavirin Effect in CHC Treatment (KIPECT) study group. Subtypes were 6, 6a, 6a/c, and 6c in 1, 3, 1, and 12 patients, respectively. Baseline median alanine transaminase level was 82 (19-236) IU/mL, and HCV RNA level was 4,791,895 (356,089- 28,844,529 IU/mL). As follow-up loss occurred in 4 patients, a total of 13 patients conformed to the treatment protocol. Patients were treated with 180 μg of peginfeterfon alfa-2a or 1.5 μg/kg of peginterferon alfa-2b except one patient who were treated with 1.0 μg/kg of peginterferon alfa-2b with 800-1200 mg of ribavirin. Among 13 patients who followed the protocol, 6 patients attained sustained virologic response (SVR), 4 patients relapsed, 2 showed null-reponse, and 1 discontinued treatment with no early virologic response. Conclusions: Although there existed inconsistent regimens in treatment for patients with genotype 6 CHC, the SVR rate was observed as 46.1% (6/13). Considering that there has been no consensus in this issue, future studies should seek to clarify issues regarding prevalence, predictors for treatment response and the impact of ethnic and genotypic factors to treatment response in genotype 6 CHC patients.
( Su Rin Shin ),( Young Seok Kim ),( Young-seok Lim ),( June Sung Lee ),( Jin Woo Lee ),( Sun Myung Kim ),( Sook-hyang Jeong ),( Joo Hyun Sohn ),( Myung Seok Lee ),( Sang Hoon Park ) 대한간학회 2017 Gut and Liver Vol.11 No.2
Background/Aims: Because of the limited geographic distribution, there have been insufficient data regarding hepatitis C virus (HCV) genotype 6 in Korea. This study aimed to investigate the clinical characteristics and available treatment outcomes of patients with genotype 6 HCV in Korea. Methods: From 2004 to 2014, data were collected from Korean patients infected with genotype 6 HCV in eight hospitals. Results: Thirty-two patients had genotype 6 HCV. The median age was 44 years, and 6c was the most common subtype. The baseline median alanine transaminase level was 88 (21 to 1,019) IU/mL, and the HCV RNA level was 1,405,000 (96,500 to 28,844,529) IU/mL. Twenty-five patients were treated with peginterferon (PEG-IFN) and ribavirin. Three follow-up losses occurred. Additionally, 13 patients attained a sustained virologic response (SVR), seven patients relapsed, and two patients exhibited a null response. The SVR rates were 40% and 75% for the 24- and more than 48- week treatments, respectively, and five of the six patients who achieved a rapid virologic response (RVR) attained a SVR. Conclusions: Korean patients infected with genotype 6 HCV are relatively young, and 6c is the most common subtype. When treated with PEG-IFN and ribavirin, the SVR rate was 52%. Similar to other genotypes, a longer duration of treatment and attainment of RVR are important for SVR. (Gut Liver 2017;11:270-275)
Hepatitis C, LC : A case of spontaneous bacterial peritonitis by achromobacter xylosoxidans (초)
( Su Rin Shin ),( Myung Seok Lee ),( Eun Jeong Choi ),( Sang Hoon Park ),( Hyoung Su Kim ),( Myoung Kuk Jang ),( Ki Tae Suk ),( Dong Joon Kim ),( Ji Won Park ),( Choong Kee Park ) 대한간학회 2011 Clinical and Molecular Hepatology(대한간학회지) Vol.17 No.3(S)
HBV : Postpartum Change of Clinical and Virologic Characteristic in Chronic Hepatitis B Patients
( Su Rin Shin ),( Hana Yoo ),( In Ho Moh ),( Ji Eun Song ),( Keun Young Lee ) 대한간학회 2013 춘·추계 학술대회 (KASL) Vol.2013 No.1
Background: It has been known that a proportion of women with chronic hepatitis B experience hepatitis flare with or without HBeAg seroconversion following delivery. However, those results were based on retrospective data. This study aimed to evaluate postpartal change of clinical and virologic characteristics in Korean women with chronic hepatitis B prospectively. Methods: We conducted a prospective cohort of pregnant women with positive HBsAg identified in an antenatal screening program between 2010 to 2012. Aminotransferases, HBeAg status, and HBV DNA level were followed up every 4-week till 24 weeks after delivery. Results: Eighteen patients with mean age of 33 (20 to 40) were enrolled. Four patients had HBeAg-positive and DNA level over 107 copies/mL, and two of them were in immune tolerance phase. Of fourteen patients with HBeAg-negative, thirteen had HBV DNA level less than 104 copies/mL. Baseline ALT level at the time of delivery was 14 (7-123) U/mL and HBV DNA was 2.9 (1.5-8.2) log10 copies/mL. Change of median ALT level was +25, +16, +25, +17, +15, +13 U/L from the initial value at 4, 8, 12, 20, and 24 weeks after delivery. Median HBV DNA level decreased by -0.2 log10 copies/mL at week-4 but did not vary significantly through the study period. Change of median DNA level was -0.2, -0.9, -0.4, -0.9, -0.9, -1.0 log10 copies/mL at 4, 8, 12, 20, and 24 weeks after delivery. Exacerbation was noted in one patient who presented HBeAg positive and active hepatitis at the time of delivery. There was no HBeAg seroconversion. Conclusions: Our data indicated that significant reactivation of chronic hepatitis B is rare in postpartal period. However, the results of this study should be interpreted in that since the majority of patients enrolled had non-proliferative phase of hepatitis B.
( Su Rin Shin ),( Sang Hoon Park ),( Myung Seok Lee ),( Jin Woo Lee ),( June Sung Lee ),( Young Seok Kim ),( Moon Seok Choi ),( Sook Hyang Jeong ),( Joo Hyun Shon ) 대한간학회 2012 춘·추계 학술대회 (KASL) Vol.2012 No.-
Background: Because of the limited geographic distribution of hepatitis C virus (HCV) genotype 6, there are insufficient data on its response to available treatment. This study was aimed to evaluate the efficacy and safety of peginterferon plus ribavirin for genotype 6 chronic hepatitis C (CHC) patients in Korea. Methods: Data of 17 patients with genotype 6 CHC who were treated with peginterferon and ribavirin at 7 hospitals affiliated with Medical College in South Korea were reviewed. Results: There were 17 patients with genotype 6 (age 35-54 years, 41% male). Among them, data of 10 patients were from K(G)yeonggi-Incheon Peginterferon Alpha and Ribavirin Effect in CHC Treatment (KIPECT) study group. Subtypes were 6, 6a, 6a/c, and 6c in 1, 3, 1, and 12 patients, respectively. Baseline median alanine transaminase level was 82 (19-236) IU/mL, and HCV RNA level was 4,791,895 (356,089- 28,844,529 IU/mL). As follow-up loss occurred in 4 patients, a total of 13 patients conformed to the treatment protocol. Patients were treated with 180 μg of peginfeterfon alfa-2a or 1.5 μg/kg of peginterferon alfa-2b except one patient who were treated with 1.0 μg/kg of peginterferon alfa-2b with 800-1200 mg of ribavirin. Among 13 patients who followed the protocol, 6 patients attained sustained virologic response (SVR), 4 patients relapsed, 2 showed null-reponse, and 1 discontinued treatment with no early virologic response. Conclusions: Although there existed inconsistent regimens in treatment for patients with genotype 6 CHC, the SVR rate was observed as 46.1% (6/13). Considering that there has been no consensus in this issue, future studies should seek to clarify issues regarding prevalence, predictors for treatment response and the impact of ethnic and genotypic factors to treatment response in genotype 6 CHC patients.
( Su Rin Shin ),( Kwang Cheol Koh ),( Geum Youn Gwak ),( Moon Seok Choi ),( Joon Hyoek Lee ),( Seung Woon Paik ),( Byung Chul Yoo ) 대한소화기기능성질환·운동학회 2010 Gut and Liver Vol.4 No.4
Background/Aims: Adefovir (ADV) is the preferred drug for treating lamivudine (LAM)-resistant hepatitis B. However, not all patients who face virologic breakthrough during LAM treatment respond to ADV. The aim of this study was to determine the factors associated with efficacy of ADV in LAM-resistant hepatitis B patients. Methods: The medical records of 231 patients who received ADV due to LAM-resistance were reviewed. Efficacy was assessed by the initial virologic response (IVR), defined as hepatitis B virus (HBV) DNA not being undetectable by real-time PCR at 6 months of ADV treatment. Results: Seventy patients (30%) achieved IVR. While ``add-on`` modality, hepatitis B e antigen (HBeAg) negativity, and low baseline HBV DNA levels were associated with IVR in univariate analysis, multivariate analysis revealed HBeAg status and the DNA level to be the significant factors. The probability of IVR achievement increased sharply per each log10 copies/mL decrement in the baseline viral load, which was 133 times in patients who had HBV DNA <10(5) copies/mL compared with those who had ≥10(8) copies/mL. Conclusions: Factors associated with the IVR were HBeAg negativity and a low baseline viral load. Therefore, when virologic breakthrough with genotypic resistance emerges during LAM therapy, ADV treatment should be considered immediately before further increases in viral load. Additional long-term follow-up data are warranted. (Gut Liver 2010;4:530-536)
Antiviral Therapy in Patients after Treatment for Hepatitis C-Related Hepatocellular Carcinoma
( Su Rin Shin ),( Seung Woon Paik ),( Geum Youn Gwak ),( Moon Seok Choi ),( Joon Hyoek Lee ),( Kwang Cheol Koh ),( Byung Chul Yoo ) 대한소화기기능성질환·운동학회 2011 Gut and Liver Vol.5 No.1
Background/Aims: Despite great progress, antiviral treatment for chronic hepatitis C in patients with prior hepatocellular carcinoma (HCC) has been rarely investigated. We evaluated the effi cacy and safety of antiviral therapy following treatment for hepatitis C-related HCC. Methods: Thirteen patients (age 34 to 60 years) who were treated with peginterferon plus ribavirin after treatment for HCC were reviewed. Results: There were 6 patients with genotype 1 and 7 patients with genotype 2. All patients showed advanced fi brosis (≥F3) but belonged to the Child-Pugh class A. Treatment was stopped in 2 patients because of recurrent HCC and in 1 patient due to a lack of early virologic response. Seven patients achieved sustained virologic response and three patients relapsed. The sustained virologic response rate was 54% overall, 17% in genotype 1, and 86% in genotype 2. No signifi cant adverse events were reported. Conclusions: Antiviral therapy should not be excluded in patients who were previously treated with HCC with genotype 2 chronic hepatitis C, in which an effi cacious antiviral treatment for chronic hepatitis C was feasible. Additional study is needed to prove the validity of antiviral therapy in patients with genotype 1 hepatitis C-related HCC. (Gut Liver 2011;5:77-81)
신수린 ( Su Rin Shin ),이명석 ( Myung Seok Lee ),박상훈 ( Sang Hoon Park ),최종수 ( Jong Soo Choi ),이경민 ( Kyung Min Lee ),김진배 ( Jin Bae Kim ),김형수 ( Hyeong Su Kim ),김정원 ( Jeong Won Kim ) 대한소화기학회 2012 대한소화기학회지 Vol.60 No.3
Breast cancer is a rare disease in men. We report a case of 53-year-old obese male, with known cryptogenic cirrhosis and hepatocellular carcinoma, presenting a tender mass on left breast. He was diagnosed with invasive intraductal carcinoma, which was consistent with a sporadic lesion. On the basis of previous literatures, obesity can be regarded as a cause for breast cancer even in men. However, there has been inconsistent data about link between liver cirrhosis and male breast cancer, which can be due to heterogenity in the etiology of cirrhosis. Through this case, it can be postulated that the risk for male breast cancer may vary according to the etiology of cirrhosis. (Korean J Gastroenterol 2012;60:182-185)
신수린 ( Su Rin Shin ),김창환 ( Chang Hwan Kim ),김성은 ( Sung Eun Kim ),박용범 ( Yong Bum Park ),이재영 ( Jae Young Lee ),모은경 ( Eun Kyung Mo ),김철홍 ( Cheol Hong Kim ),엄광석 ( Kwang Seok Eom ),장승훈 ( Seung Hun Jang ),김동 대한결핵 및 호흡기학회 2006 Tuberculosis and Respiratory Diseases Vol.61 No.3
배경: 근치적 항결핵제의 유용에도 불구하고, 결핵으로 사망하는 환자는 증가하고 있다. 다제내성결핵과 HIV 감염이 높은 사망률과 관련되어 있지만, HIV 감염률이 낮은 지역에서는 다른 요소들이 사망과 관련되어 있을 가능성이 있다. 이에 결핵으로 입원한 환자에서 병원내 사망과 관련된 인자들을 알아보고자 하였다. 방법: 2003년 1월 1일부터 2004년 12월 31일까지 한림대학교 병원에 결핵으로 확진되어 치료한 신환에서 사망한 환자 27명과 호전되어 퇴원한 환자 중 나이와 성별을 짝지은 54명을 대조군으로 비교분석하였다. 결과: 사망군의 평균 나이는 60±16세이며, 남자가 70%였다. 대조군에 비해 사망군에서 혈색소, 알부민과 콜레스테롤이 유의하게 낮았으며(p<0.05), 혈액요소질소, AST, C-reactive protein는 유의하게 높았다(p<0.05). 사망군에서 대조군에 대해 결핵의 기왕력은 차이가 없었으며, 방사선학적 중증도, 동반질환, 내원시 호흡곤란, 응급실을 통한 입원과 초기 중환자실 치료가 유의하게 높았다(p<0.05). 다중회귀분석을 통해 알부민과 초기 중환자실 치료가 독립적으로 사망에 영향을 미치는 인자로 밝혀졌다(p<0.05). 결론: 심한 영양결핍을 동반한 중증 결핵 환자는 사망에 고위험군으로 결핵 환자의 조기 발견 및 치료에 개선이 필요하며, 효율적인 공공 보건 교육, 검진정책과 환자관리가 중요할 것으로 사료된다. Study objectives: To determine the factors associated with mortality after an in-hospital diagnosis of tuberculosis in a region with low levels of HIV coinfection. Methods: From January 2003 to December 2004, all subjects who were > 15 years of age and had received a diagnosis of tuberculosis were registered. The clinical, radiological and laboratory aspects of the patients who died (n=27) were compared with those of an age and gender matched control population(n=54). Logistic regression analyses were carried out, which included age, gender, hospital admission source, initial site of admission, dyspnea, general weakness and initial laboratory data. Results: The mean age of the patients was 60±16 years and male patients outnumbered female patients. Univariate analysis identified hemoglobin, blood urea nitrogen, albumin, cholesterol, aspartate aminotransferase (AST), C-reactive protein and the risk factors for tuberculosis to be significantly associated with mortality. Among the characteristics of disease presentation and treatment, emergency department admission, intensive care unit, disease severity, general weakness and dyspnea at the time of admission were associated with mortality. Multiple regression analysis revealed the initial management in the intensive care unit and lower serum albumin to be independently associated with mortality. Conclusion: The markers of disease chronicity and severity appear to be associated with in-hospital mortality. Identifying potentially reversible factors such as malnutrition and respiratory failure suggests specific intervention that might lead to an improvement in the patients` outcomes. (Tuberc Respir Dis 2006; 61: 233-238)